Apellis Pharmaceuticals Inc.

46.26-0.7400-1.57%Vol 1.82M1Y Perf -25.48%
Jun 24th, 2022 16:00 DELAYED
BID18.48 ASK61.29
Open47.00 Previous Close47.00
Pre-Market- After-Market46.26
 - -  - -%
Target Price
70.38 
Analyst Rating
Strong Buy 1.46
Potential %
52.14 
Finscreener Ranking
★+     42.41
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     40.60
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     40.47
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
41.23 
Earnings Rating
Sell
Market Cap4.93B 
Earnings Date
8th Aug 2022
Alpha0.02 Standard Deviation0.20
Beta1.63 

Today's Price Range

45.1047.94

52W Range

27.5073.00

5 Year PE Ratio Range

-8.20-7.40

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
4.80%
1 Month
13.13%
3 Months
-6.13%
6 Months
-5.90%
1 Year
-25.48%
3 Years
94.21%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APLS46.26-0.7400-1.57
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
7.80
8.80
0.31
0.46
-38.80
Leverage Ratio 6.70
ProfitabilityValueIndustryS&P 500US Markets
92.00
-843.10
-841.30
-
-89.24
RevenueValueIndustryS&P 500US Markets
80.94M
0.76
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-1.36-1.42-4.41
Q04 2021-1.32-1.61-21.97
Q03 2021-1.73-2.28-31.79
Q02 2021-1.70-2.72-60.00
Q01 2021-1.69-2.32-37.28
Q04 2020-0.480.93293.75
Q03 2020-1.53-1.79-16.99
Q02 2020-1.30-1.57-20.77
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.36-8.80Negative
9/2022 QR-1.35-3.85Negative
12/2022 FY-5.51-4.55Negative
12/2023 FY-4.29-26.55Negative
Next Report Date8th Aug 2022
Estimated EPS Next Report-1.36
Estimates Count8
EPS Growth Next 5 Years %19.30
Volume Overview
Volume1.82M
Shares Outstanding106.52K
Shares Float77.71M
Trades Count14.95K
Dollar Volume84.10M
Avg. Volume945.06K
Avg. Weekly Volume941.43K
Avg. Monthly Volume812.05K
Avg. Quarterly Volume1.08M

Apellis Pharmaceuticals Inc. (NASDAQ: APLS) stock closed at 46.26 per share at the end of the most recent trading day (a -1.57% change compared to the prior day closing price) with a volume of 1.82M shares and market capitalization of 4.93B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 374 people. Apellis Pharmaceuticals Inc. CEO is Cedric Francois.

The one-year performance of Apellis Pharmaceuticals Inc. stock is -25.48%, while year-to-date (YTD) performance is -2.16%. APLS stock has a five-year performance of %. Its 52-week range is between 27.5 and 73, which gives APLS stock a 52-week price range ratio of 41.23%

Apellis Pharmaceuticals Inc. currently has a PE ratio of -5.60, a price-to-book (PB) ratio of 10.17, a price-to-sale (PS) ratio of 58.09, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -73.44%, a ROC of -121.89% and a ROE of -274.60%. The company’s profit margin is -89.24%, its EBITDA margin is -841.30%, and its revenue ttm is $80.94 Million , which makes it $0.76 revenue per share.

Of the last four earnings reports from Apellis Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-1.36 for the next earnings report. Apellis Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Apellis Pharmaceuticals Inc. is Strong Buy (1.46), with a target price of $70.38, which is +52.14% compared to the current price. The earnings rating for Apellis Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Apellis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Apellis Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.52, ATR14 : 2.78, CCI20 : 144.19, Chaikin Money Flow : 0.10, MACD : 0.43, Money Flow Index : 61.04, ROC : 2.50, RSI : 57.79, STOCH (14,3) : 83.66, STOCH RSI : 0.84, UO : 59.88, Williams %R : -16.34), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Apellis Pharmaceuticals Inc. in the last 12-months were: A. Sinclair Dunlop (Option Excercise at a value of $376 516), Alec Machiels (Option Excercise at a value of $57 405), Alec Machiels (Sold 21 500 shares of value $980 928 ), Cedric Francois (Option Excercise at a value of $62 107), David Watson (Option Excercise at a value of $293 786), David Watson (Sold 16 771 shares of value $813 573 ), Federico Grossi (Option Excercise at a value of $173 441), Federico Grossi (Sold 9 250 shares of value $399 253 ), Lukas Scheibler (Option Excercise at a value of $593 182), Lukas Scheibler (Sold 48 508 shares of value $2 374 439 ), Mark Jeffrey DeLong (Option Excercise at a value of $278 180), Mark Jeffrey DeLong (Sold 19 000 shares of value $912 860 ), Nicole Perry (Option Excercise at a value of $7 520), Nicole Perry (Sold 2 000 shares of value $127 990 ), Pascal Deschatelets (Option Excercise at a value of $148 198), Pascal Deschatelets (Sold 16 000 shares of value $706 800 ), Victoria L. Brown (Sold 2 698 shares of value $121 410 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (84.62 %)
10 (83.33 %)
11 (84.62 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (7.69 %)
1 (8.33 %)
2 (15.38 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (7.69 %)
1 (8.33 %)
0 (0.00 %)
Summary RatingStrong Buy
1.46
Strong Buy
1.50
Strong Buy
1.31

Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.

CEO: Cedric Francois

Telephone: +1 617 977-5700

Address: 100 Fifth Avenue, Waltham 02451, MA, US

Number of employees: 374

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

74%26%

Bearish Bullish

62%38%

TipRanks News for APLS

Tue, 24 May 2022 12:45 GMT Apellis Pharmaceuticals (APLS) Receives a Buy from Goldman Sachs

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 10:36 GMT Apellis Pharmaceuticals (APLS) Gets a Buy Rating from Needham

- TipRanks. All rights reserved.

Tue, 05 Apr 2022 02:40 GMT Analysts Offer Insights on Healthcare Companies: Calithera Bio (CALA), Apellis Pharmaceuticals (APLS) and BridgeBio Pharma (BBIO)

- TipRanks. All rights reserved.

Mon, 04 Apr 2022 16:42 GMT Apellis Pharmaceuticals (APLS) Gets a Buy Rating from J.P. Morgan

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 10:23 GMT Apellis Pharmaceuticals (APLS) Gets a Buy Rating from Robert W. Baird

- TipRanks. All rights reserved.

News

Stocktwits